Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-304: Tarlatamab vs standard chemotherapy in relapsed small cell lung cancer
CTR20232049Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Jul 2023; status: completed.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20232049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232049.